In the case of Myc, there has already been a phase I clinical trial concerning synthetic lethality of Myc by assessing the safety and tolerability of weekly dinaciclib in combination with pembrolizumab in patients with advanced breast cancer (NCT01676753). Here, MYC is linked to breast carcinoma.